[Cystoid macular oedema after fingolimod treatment in multiple sclerosis].

نویسندگان

  • V M Asensio-Sánchez
  • L Trujillo-Guzmán
  • R Ramoa-Osorio
چکیده

CASE REPORT A woman, treated with immunomodulatory and immunosuppressive drugs for multiple sclerosis, developed macular oedema 4 months after oral fingolimod administration. The patient was previously seen by an ophthalmologist, with a normal anterior segment and funduscopic examination. Four months after the treatment she referred to decreased visual acuity in both eyes. The funduscopic and OCT examination now revealed cystoid macular oedema (CME). DISCUSSION Attention to visual changes and periodic funduscopic examinations are an important part of monitoring while using fingolimod. In our patient early recognition and discontinuation of fingolimod did not result in resolution of the CME.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Early Bilateral Cystoid Macular Oedema Secondary to Fingolimod in Multiple Sclerosis

We report a case of fingolimod-associated bilateral cystoid macular oedema in a patient with multiple sclerosis (MS). A 34-year-old female, diagnosed with MS at age of 30, developed bilateral blurred vision 5 days after initiation of fingolimod. She was misdiagnosed as optic neuritis initially and fingolimod was only discontinued 3 weeks after onset of her visual symptoms when OCT showed promin...

متن کامل

Acute Anterior Uveitis in a Patient Taking Fingolimod (FTY720) for Multiple Sclerosis

Fingolimod is an oral sphingosine-1-phosphate (S1P) receptor modulator and the first oral therapy for relapsing-remitting multiple sclerosis. Its use has been complicated by a low rate of cystoid macular edema usually in the first 3 months after commencement of the medication. We report the case of a 34-year-old male with relapsing-remitting multiple sclerosis, who developed acute anterior uvei...

متن کامل

Cystoid macular edema associated with fingolimod use for multiple sclerosis.

Fingolimod is the first oral drug approved by the US Food and Drug Administration for multiple sclerosis (MS). It is a sphingosine-1phosphate–receptor modulator that prevents lymphocyte egress from lymph nodes and enhances astrocyte function. In this retrospective case series, 4 eyes from 3 patients developed cystoid macular edema (CME) after initiating fingolimod therapy. The study was approve...

متن کامل

Fingolimod-associated macular oedema.

Jasani KM, et al. BMJ Case Rep 2017. doi:10.1136/bcr-2016-218912 Description A 54-year-old female with history of relapsing remitting multiple sclerosis (MS) was switched from interferon beta-1A (Avonex, Biogen) to fingolimod (Gilenya, Novartis) therapy after having two clinical relapses within 2 years while on treatment. As part of her treatment protocol, she was referred to the local ophthalm...

متن کامل

Evaluation of the Incidence of Macular Edema in Patients with Multiple Sclerosis Treated with Fingolimod

Purpose: To determine the incidence of macular edema in patients with MS treated with 0.5 mg Fingolimod. Methods: In this prospective descriptive-analytic study a total of 115 patients were enrolled. Patients underwent an ophthalmologic examination before starting the treatment. In the fourth month after starting the treatment for each patient, regardless of whether or not being marked, the oph...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Archivos de la Sociedad Espanola de Oftalmologia

دوره 89 3  شماره 

صفحات  -

تاریخ انتشار 2014